NIH-funded research NIH-funded research

Developing a vaccine using Vero cells for respiratory syncytial virus (RSV).

Official title: Task V08: Process Development for Scale-up of Vero Cells on Micro-Carriers for Manufacturing of a Live-Attenuated RSV Vaccine

Funded at Idt Biologika Gmbh · NIH-10002373 · Data updated 2026-11-12

This study is working on creating a new vaccine to help protect against respiratory syncytial virus (RSV) by improving how it's made, so it can be safely tested in people.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionIdt Biologika Gmbh
NIH-funded
Lab location1 site (Dessau-Rosslau, Germany)
Project startMay 15, 2018
Project endMay 14, 2028
Funding year2019
Award (this year)$2,656,200
NIH project number272201800011I-0-759301900311-1
Project IDNIH-10002373 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for participation or benefit from this research would include infants and young children who are at high risk for severe RSV infections.

Less likely to help

Patients who are not at risk for RSV or those who have already been vaccinated against it may not receive any benefit from this research.

What this research studies

This research focuses on the development and manufacturing processes for a live-attenuated vaccine against respiratory syncytial virus (RSV) using Vero cells grown on micro-carriers. The project involves optimizing the production methods to ensure compliance with good manufacturing practices (cGMP) for clinical trials. By utilizing advanced techniques and regulatory support, the research aims to facilitate the introduction of effective vaccines against RSV and other infectious diseases.

Why it matters

Potential benefit: If successful, this research could lead to the development of a safe and effective vaccine for RSV, potentially reducing the incidence of this common respiratory infection.

How similar studies have gone: Other research has shown success in developing vaccines using similar methodologies, indicating a promising approach for this project.

Where this research is happening

  • Idt Biologika Gmbh
    Dessau-Rosslau, Germany
    Active

Researchers

  • Principal investigator: Cristina, Arbelo — Idt Biologika Gmbh
  • Study coordinator: Cristina, Arbelo

Related research

Other NIH-funded projects on the same topics.

  • Developing new vaccines for infectious diseases and bioterrorism

    This study is all about creating new vaccines to help protect people from infectious diseases, including those that could come from bioterrorism or drug-resistant germs, so that patients can have better options for staying healthy.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-9746965

  • Creating master cell banks for new SARS-CoV-2 vaccines

    This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-11202800

  • Creating materials for testing new influenza vaccines

    This study is working on creating and improving materials for new flu vaccines, which could help keep you and others safer from the flu and similar illnesses.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-11167540

  • Creating master cell banks for new SARS-CoV-2 vaccines

    This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-11080845

  • Creating vaccines and biologics to combat infectious diseases

    This study is working on creating new vaccines to help protect people from infections like those caused by E. coli, so that patients can have better options for staying healthy and safe from serious diseases.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-10701630

  • Developing a vaccine for Staphylococcus aureus

    This study is working on creating a new vaccine to help protect people from Staphylococcus aureus infections, which can be tough to treat because the bacteria resist many antibiotics, and it aims to make this vaccine safe and effective for future use.

    NIH research Idt Biologika Gmbh · Dessau-Rosslau, Germany · NIH-10475959

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.